VALENCIA, Calif.--()--MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at upcoming conferences.
- Rodman & Renshaw Annual Global Investment Conference on Monday, September 10, 2012 at 10:25 AM (ET) at the Waldorf-Astoria, New York City.
- Morgan Stanley Global Healthcare Conference on Wednesday, September 12, 2012 at 10:55 AM (ET) at the Grand Hyatt New York, New York City.
- Imperial Capital Global Opportunities Conference on Wednesday, September 19, 2012 at 12:30 PM (ET) at the Waldorf-Astoria, New York City.
Interested parties can access a link to the live webcast of the presentations from the News & Events section of the Company's website at http://www.mannkindcorp.com.
About MannKind Corporation
MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its lead product candidate, AFREZZA®, is in late stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. MannKind maintains a website at www.mannkindcorp.com to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.